Peripheral Expression of CXCL10 Gene in Chronic Hepatitis C Patients Treated with Sofosbuvir, Daclatasvir, and Ribavirin

被引:5
|
作者
Afzal, Maira [1 ]
Ali, Amjad [2 ]
Sheikh, Nadeem [3 ]
Rafique, Shazia [4 ]
Idrees, Muhammad [4 ]
机构
[1] Univ Punjab, Ctr Appl Mol Biol CAMB, Mol Virol Lab, Lahore, Pakistan
[2] Hazara Univ Mansehra, Dept Genet, Khyber Pakhtunkhwa 21310, Pakistan
[3] Univ Punjab, Dept Zool, Lahore, Pakistan
[4] Univ Punjab, Ctr Excellence Mol Biol CEMB, Div Mol Virol, Lahore, Pakistan
来源
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH | 2020年 / 40卷 / 06期
关键词
CXCL10; expression; HCV; DAAs; patients; HEPATOCELLULAR-CARCINOMA; ANTIVIRAL THERAPY; VIRUS-INFECTION; PEGINTERFERON ALPHA-2A; PEGYLATED INTERFERON; TREATMENT-NAIVE; PLUS RIBAVIRIN; VIRAL RESPONSE; IP-10; CXCL10; GENOTYPE;
D O I
10.1089/jir.2019.0185
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hepatitis C virus (HCV) causes persistent infection and invades host's innate and adaptive immune systems. During the eradication of this pathogen, the components of immune system may cause bystander damage to host, which might be even worse than the viral pathogenesis. Thus, the therapy should not only eliminate primary virus infection but also improve the inflammatory immune responses. The breakthrough of interferon free direct acting antiviral (DAA) drugs has provided the opportunity to unravel the association of HCV with immune response. This study aimed to examine the expression level of C-X-C motif chemokine ligand 10 (CXCL10) in the Peripheral blood mononuclear cells (PBMCs) of HCV infected patients treated with DAAs + Ribavirin. In this study we analyzed the expression levels ofCXCL10mRNA in the 90 chronic HCV patients using quantitative PCR (qPCR) prior, after, and during therapy with sofosbuvir/ribavirin (SOF+RBV) and sofosbuvir/daclatasvir/ribavirin (SOF+DCV+RBV), and further, the results were analyzed relative to treatment response. Significantly elevatedCXCL10mRNA was seen in naive patients having higher viral load (P = 0.005) and those suffering from hepatocellular carcinoma (P = 0.006). HCV patients had remarkable decline inCXCL10level after 4, 12, and 24 weeks of therapy with DAAs. An approximate one-fold decrease was observed in patients who attained sustained virological response compared to untreated patients (P< 0.0001). Comparing the 2 regimens, the reduction in peripheralCXCL10expression was more pronounced in patients undergoing SOF+DCV+RBV therapy. The current study implicitly shows the role ofCXCL10as an indicator of disruption of host-virus equilibrium and consequent pathogenesis of HCV during successful antiviral therapy. Furthermore, the drop inCXCL10level after HCV viral clearance might reflect the DAA-induced alleviation in the extrahepatic manifestation of this infection.
引用
收藏
页码:301 / 309
页数:9
相关论文
共 50 条
  • [21] Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study
    Yoshiiku Kawakami
    Hidenori Ochi
    Clair Nelson Hayes
    Michio Imamura
    Masataka Tsuge
    Takashi Nakahara
    Yoshio Katamura
    Hiroshi Kohno
    Hirotaka Kohno
    Keiji Tsuji
    Shintaro Takaki
    Nami Mori
    Yohji Honda
    Keiko Arataki
    Shoichi Takahashi
    Shinsuke Kira
    Toru Tamura
    Kazunari Masuda
    Toshio Nakamura
    Masaya Kikkawa
    Kazuaki Chayama
    Journal of Gastroenterology, 2018, 53 : 548 - 556
  • [22] Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients
    Mohamed, Mohamed S.
    Hanafy, Amr S.
    Bassiony, Mohamed A. A.
    Hussein, Samia
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 29 (12) : 1368 - 1372
  • [23] Real life experience with Sofosbuvir plus Daclatasvir With or Without Ribavirin for Treatment of Chronic hepatitis C Genotype 4 Patients.
    Shiha, Gamal
    Soliman, Reham
    Elbasiony, Mohamed
    Hassan, Ayman
    Mikhail, Nabiel
    HEPATOLOGY, 2017, 66 : 835A - 835A
  • [24] Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study
    Kawakami, Yoshiiku
    Ochi, Hidenori
    Hayes, Clair Nelson
    Imamura, Michio
    Tsuge, Masataka
    Nakahara, Takashi
    Katamura, Yoshio
    Kohno, Hiroshi
    Kohno, Hirotaka
    Tsuji, Keiji
    Takaki, Shintaro
    Mori, Nami
    Honda, Yohji
    Arataki, Keiko
    Takahashi, Shoichi
    Kira, Shinsuke
    Tamura, Toru
    Masuda, Kazunari
    Nakamura, Toshio
    Kikkawa, Masaya
    Chayama, Kazuaki
    JOURNAL OF GASTROENTEROLOGY, 2018, 53 (04) : 548 - 556
  • [25] Efficacy and safety of Sofosbuvir Plus Daclatasvir bilayer tablet with or without Ribavirin in patients with chronic hepatitis C genotype 4 Infection
    Hassany, Mohamed
    Ramadan, Sameh
    Moustafa, Ehab
    Eysa, Basem
    Zidan, Ahmed
    Hassan, Amany
    Abdulaziz, Heba
    Afify, Shimaa
    Saeed, Mohamed
    Shalabi, Hanaa
    Gomaa, Asmaa
    Allam, Naglaa
    Abdelsameea, Eman
    Badr, Reda
    Sabry, Aliaa
    Alkhatib, Alzhraa
    Sameh, Heba
    Elhelbawy, Mostafa
    Radwan, Ahmed
    Hassany, Sahar
    Attia, Enas
    Razek, Mai Abdel
    Elamrawy, Fatema
    Medhat, Waseem
    Hamed, Omar
    Safwat, Dalia
    Ezzat, Doris
    Prince, Khaled
    Waked, Imam
    JOURNAL OF HEPATOLOGY, 2023, 78 : S1212 - S1212
  • [26] long-term follow up of chronic hepatitis C Egyptian patients treated with sofosbuvir/daclatasvir regimen
    Elnoemany, Karim
    Badr, Mohamed
    Elnadry, Mohamed
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 137 - 137
  • [27] SOFOSBUVIR/ DACLATASVIR AND NOT SOFOSBUVIR/VELPATASVIR RESULTS IN ADVERSE LIPID PROFILE CHANGES IN CHRONIC HEPATITIS C PATIENTS
    Kolhe, Kailash M.
    Ingle, Meghraj
    Pandey, Vikas
    Gattani, Mayur
    Chauhan, Shamsher
    Khairnar, Harshad
    Vishwanathan, Deepti
    Chaudhary, Vipul
    Jadhav, Rahul
    Walke, Swapnil
    Shukla, Akash
    GASTROENTEROLOGY, 2020, 158 (06) : S1321 - S1322
  • [28] Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders
    Walsh, C. E.
    Workowski, K.
    Terrault, N. A.
    Sax, P. E.
    Cohen, A.
    Bowlus, C. L.
    Kim, A. Y.
    Hyland, R. H.
    Han, B.
    Wang, J.
    Stamm, L. M.
    Brainard, D. M.
    McHutchison, J. G.
    von Drygalski, A.
    Rhame, F.
    Fried, M. W.
    Kouides, P.
    Balba, G.
    Reddy, K. R.
    HAEMOPHILIA, 2017, 23 (02) : 198 - 206
  • [29] Thyroid disturbance related to chronic hepatitis C infection: role of CXCL10
    Seguro Danilovic, Debora Lucia
    Mendes-Correa, Maria Cassia
    Chammas, Maria Cristina
    Zambrini, Heverton
    Barros, Raffaelle K.
    Marui, Suemi
    ENDOCRINE JOURNAL, 2013, 60 (05) : 583 - 590
  • [30] Effect of sofosbuvir and daclatasvir treatment on the blood indices in patients with chronic hepatitis C virus
    Fouad, Rabab
    El-Akel, Wafaa
    Elmakhzangy, Hesham
    Lithy, Rania M.
    Sherif, Mirella
    Fateen, Mohamed
    Hassany, Mohamed
    Abdel-Razek, Wael
    Doss, Wahid
    ARAB JOURNAL OF GASTROENTEROLOGY, 2025, 26 (01) : 78 - 83